The efficacy of Delamanid against tuberculosis

Delamanid is indicated for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants weighing at least 10kg, for whom an effective treatment regimen cannot be formed due to drug resistance or tolerance. Tuberculosis is an infection caused by Mycobacterium tuberculosis (Mycobacterium tuberculosis), and the active substance in delamanid is an antibiotic that fights Mycobacterium tuberculosis. After being marketed, it was believed that its benefits outweighed its risks, and it has been shown to be suitable for patients with multidrug-resistant TB that affects the lungs. Although the main study was short in duration and follow-up studies were insufficient, the effects shown after the first 2 months of treatment may persist throughout the treatment period. Ongoing clinical studies of delamanid will provide confirmation of long-term effectiveness.